Weight loss
Semaglutide Injection
Prescribed by a licensed U.S. clinician · Compounded by a licensed U.S. pharmacy
$79 /mo
Same price at every dose, 0.25 to 2.4 mg
You won't be charged unless a licensed clinician prescribes it.
- LegitScript certified
- U.S.-licensed clinicians
- U.S.-licensed pharmacies
A compounded injectable GLP-1 treatment using semaglutide. Read more
Active ingredients: Semaglutide (0.25 to 2.4 mg weekly)*
Typical supply: One injection a week. Each month is a 30-day supply at the dose your clinician prescribes.
Compounded GLP-1s are prepared with an added vitamin or other ingredient, such as vitamin B12. Which one depends on the pharmacy that fills your prescription, and your pharmacy label lists exactly what is in your medication.
Your clinician decides exactly what you receive, and your pharmacy label shows it.
Every weekly dose, same price
- 0.25 mg
- 0.5 mg
- 1 mg
- 1.5 mg
- 2 to 2.4 mg
- If you're not prescribed, you pay nothing.
- No membership fee and no clinician fee.
- Free, discreet shipping.
Tirzepatide is $60 more a month and acts on two appetite hormones instead of one. In the SURMOUNT-5 head-to-head trial, people taking it lost 20.2% of their body weight on average, compared with 13.7% on semaglutide. Compare the resultsSURMOUNT-5 studied specific FDA-approved tirzepatide and semaglutide regimens. Avono compounded medications were not studied in SURMOUNT-5, are not FDA-approved, and individual results vary.
FDA-approved injectable semaglutide products have a substantial evidence base in chronic weight management. The compounded semaglutide offered through Avono is a custom-compounded prescription formulation and is not FDA-approved.
Suggested add-ons
- For nauseaOndansetron$45
- For sleepTrazodone
Choose them in your intake. No separate visit. Why we suggest them
You won't be charged unless a licensed clinician prescribes it. Your card is held when you finish your visit, and the hold is released if you are not prescribed. The charge shows as CareValidate, the platform that runs our visits and payments.
No membership. Month-to-month plans can be canceled before your next refill. Not sure this is the one? See how tirzepatide compares or answer a few quick questions.
- TodayOnline visit, a few minutes
- Usually a few business daysClinician review
- If prescribedShips to your door
- Reviewed by a licensed U.S. clinician
- Filled by a state-licensed U.S. pharmacy
- Discreet shipping, no membership
Prescription only. A licensed clinician decides whether it is right for you from your health answers. Individual results vary. Your secure online visit takes a few minutes.
How it works
What happens after you start?
You won't be charged unless a licensed clinician prescribes it.
- 01Today
Start your online visit
Answer health questions online. No appointment and no waiting room. Your card is held, not charged.
- 02Usually a few business days
Clinician review
A licensed U.S. clinician reviews your answers and decides whether this treatment is right for you. If it isn't, the hold on your card is released and you are not charged.
- 03If prescribed
Made and shipped
A licensed U.S. pharmacy in our network prepares your medication and ships it in plain packaging. Most orders arrive within 3 to 5 days.
- 04Ongoing
Help when you need it
Questions about your treatment or your order? Message us anytime through your patient portal.
One price
Everything in the price.
- Licensed U.S. clinician review. No visit fee.
- Your medication. From a licensed U.S. pharmacy.
- Free, discreet shipping.
- No membership. Nothing to join, nothing extra each month.
- Same price at every dose. From 0.25 to 2.4 mg.
Before you choose
Why we suggest starting with tirzepatide
Both are once-weekly GLP-1 injections. In the only head-to-head trial of the two for weight loss, tirzepatide led to more weight loss.
- More weight loss. In SURMOUNT-5, people on tirzepatide lost 20.2% of their body weight on average over 72 weeks, compared with 13.7% on semaglutide.
- Nearly twice as many big results. 48.4% of people on tirzepatide lost 20% or more of their body weight, compared with 27.3% on semaglutide.
- Two hormones, not one. Tirzepatide acts on two appetite and metabolism hormones, GIP and GLP-1. Semaglutide acts on GLP-1 only.
- The same kind of side effects. In the trial, the most common side effects in both groups were stomach-related, generally mild to moderate.
- The price difference. Tirzepatide is $139 a month at every dose, $60 more than semaglutide at $79.
Semaglutide can still be the right choice, for example if the lower price matters most to you or your clinician prefers it for you.
Your secure online visit takes a few minutes.
SURMOUNT-5 · NEJM 2025
48.4% on tirzepatide lost 20% or more
27.3% on semaglutide lost 20% or more
Important: SURMOUNT-5 studied specific FDA-approved tirzepatide and semaglutide regimens. Avono compounded medications were not studied in SURMOUNT-5, are not FDA-approved, and individual results vary.
Suggested add-ons
Plan ahead for nausea and sleep
Nausea is the most common side effect of semaglutide. In the trials behind Wegovy, the FDA-approved semaglutide, 44% of people had nausea, compared with 16% on placebo. It is most likely in the first weeks and after each dose increase. Sleep can also be harder while you change how much and when you eat. We suggest adding ondansetron for nausea and trazodone for sleep when you start, so you have them on hand if you need them.
For nausea
Ondansetron ODT 4 mg
$45 for 20 tablets, taken as needed
Nausea is the most common reason people struggle in the first weeks of GLP-1 treatment, especially after a dose increase. Ondansetron is a tablet that dissolves on the tongue and helps settle it, so you can stay on track.
Why add it
- Blocks the serotonin signals that trigger nausea and vomiting.
- Dissolves on the tongue in seconds, with no water needed.
- Take it only when you need it, not every day.
FDA-approved for other types of nausea; using it for GLP-1 nausea is your clinician's call.
For sleep
Trazodone
50, 100 or 150 mg tablets. Price shown in your GLP-1 intake
Sleep can be harder when you change how much and when you eat. Trazodone is a prescription medicine that, at low doses, is often used to help people fall asleep and stay asleep. Unlike many prescription sleeping pills, it is not a controlled substance.
Why add it
- Taken at bedtime, at a low dose your clinician sets.
- Not a controlled substance, unlike many prescription sleeping pills.
- Chosen in the same GLP-1 intake, with no separate visit.
FDA-approved for depression; using it for sleep is off-label and your clinician's call. It can cause next-day drowsiness and dizziness, and like all antidepressants it carries a boxed warning about suicidal thoughts in people under 25.
How to add them: choose them in your GLP-1 intake. There is no separate visit, and a licensed clinician decides whether each one is right for you.
Prescription required. Compounded medications are not FDA-approved. Side-effect figures come from the prescribing information for the FDA-approved product. Avono compounded medications were not studied in those trials.
What to expect
How the injection works
This is a shot you give yourself at home, once a week, just under the skin. It is not a pill, and it is not a prefilled pen.
A vial and syringe, not a pen
Brand-name medicines such as Ozempic, Wegovy and Mounjaro come in prefilled pens that click to a set dose. Compounded medication comes in a small vial. Each week, you draw your dose into a syringe and inject it yourself.
Measure exactly what your label says
Your pharmacy label tells you how many units to draw. Follow it exactly, and ask your clinician or pharmacist before your first dose if anything is unclear. The FDA has reported overdoses from mixing up units, milliliters and milligrams.
Under the skin, once a week
Inject into your belly, thigh or upper arm on the same day each week, switching spots each time. The needle is short and thin, the kind used for insulin.
Help when you need it
Read the instructions that come with your medication. Questions before or after a dose? Message us anytime through your patient portal.
Ozempic and Wegovy are trademarks of Novo Nordisk. Mounjaro is a trademark of Eli Lilly and Company. Avono compounded medications are not FDA-approved and are not the same as these brand-name products. FDA alert on dosing errors
What it does
Semaglutide is a GLP-1 receptor agonist. It mimics GLP-1, a gut hormone involved in appetite and blood-sugar signaling. It is not a sex hormone or steroid. Semaglutide can reduce hunger, increase fullness and slow stomach emptying.
What's in it
Semaglutide (0.25 to 2.4 mg weekly)
- What it is
- Semaglutide is a GLP-1 receptor agonist.
- Hormone?
- Acts on hormone signaling
- Why it's here
- It mimics GLP-1, a gut hormone involved in appetite and blood-sugar signaling.
- What to know
- It is not a sex hormone or steroid.
Compounded GLP-1s are prepared with an added vitamin or other ingredient, such as vitamin B12. Which one depends on the pharmacy that fills your prescription, and your pharmacy label lists exactly what is in your medication.
Why choose this one?
Best for
Men and women working on weight loss who want the GLP-1 medication with the longest track record, or a lower monthly price.
Why choose this one
It acts on one appetite hormone (GLP-1) and has been used for weight management the longest. In the SURMOUNT-5 head-to-head trial, average weight loss was 13.7% on semaglutide and 20.2% on tirzepatide over 72 weeks. That is why most people start with tirzepatide.
SURMOUNT-5 studied specific FDA-approved tirzepatide and semaglutide regimens. Avono compounded medications were not studied in SURMOUNT-5, are not FDA-approved, and individual results vary.
Why choose Tirzepatide Injection instead?
Tirzepatide acts on both GIP and GLP-1 and produced greater average weight loss than semaglutide in the SURMOUNT-5 head-to-head trial of the studied FDA-approved products and regimens.
Same price at every dose
| Avono level | Weekly dose | Monthly price |
|---|---|---|
| Level 1 | 0.25 mg | $79/month |
| Level 2 | 0.50 mg | $79/month |
| Level 3 | 1.00 mg | $79/month |
| Level 4 | 1.50 mg | $79/month |
| Level 5+ | 2.00 to 2.40 mg | $79/month |
Your clinician determines whether treatment is appropriate and what dose is appropriate for you. Not every patient will use every dose level, and dose changes should only be made under clinician guidance. These Avono levels are a pricing reference, not a dosing schedule, and not the labeled schedule for any FDA-approved product.
Compare your options
Tirzepatide vs semaglutide
| Tirzepatide injection | Semaglutide injection | |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist |
| Price at every dose | Same monthly price at every dose, 2.5 to 15 mg | Same monthly price at every dose, 0.25 to 2.4 mg |
| Head-to-head evidence | SURMOUNT-5 (NEJM 2025), 72 weeks | SURMOUNT-5 (NEJM 2025), 72 weeks |
| Studied average weight reduction in SURMOUNT-5 | 20.2% (tirzepatide 10 or 15 mg) | 13.7% (semaglutide 1.7 or 2.4 mg) |
| Lost 20% or more of body weight in SURMOUNT-5 | 48.4% of participants | 27.3% of participants |
| Average waist reduction in SURMOUNT-5 | 18.4 cm | 13.0 cm |
| Common side effects | Mostly gastrointestinal, generally mild to moderate, especially during dose escalation | Mostly gastrointestinal, generally mild to moderate, especially during dose escalation |
| Clinician review | Required | Required |
| Compounded status | Compounded; not FDA-approved | Compounded; not FDA-approved |
| Price at Avono | From $139 per month | From $79 per month |
SURMOUNT-5 studied specific FDA-approved tirzepatide and semaglutide regimens. Avono compounded medications were not studied in SURMOUNT-5, are not FDA-approved, and individual results vary.
Read: Tirzepatide or Semaglutide? How to Choose the Right GLP-1 for You
Benefits and evidence
STEP 1: semaglutide 2.4 mg
- What the study found
- 14.9%
- Who was studied
- 1,961 adults with overweight or obesity, without diabetes
- What it means
- In the STEP 1 trial, adults receiving studied semaglutide 2.4 mg plus lifestyle intervention lost an average 14.9% of body weight over 68 weeks.
- Important context
- Study involved a specific semaglutide formulation and dose. Individual results vary. Compounded medications are not FDA-approved. Once-weekly subcutaneous semaglutide plus lifestyle intervention · 2.4 mg once weekly · 68 weeks
- Source
- Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med, 2021, PMID 33567185
Evidence for Semaglutide, not for this exact formula
SURMOUNT-5: tirzepatide vs semaglutide
- What the study found
- 20.2% vs 13.7%
- Who was studied
- 751 adults with obesity, without diabetes
- What it means
- In the first head-to-head trial, adults taking tirzepatide lost more weight on average than those taking semaglutide over 72 weeks.
- Important context
- Once-weekly subcutaneous tirzepatide vs semaglutide · Tirzepatide 10 or 15 mg; semaglutide 1.7 or 2.4 mg · 72 weeks
- Source
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity N Engl J Med, 2025, PMID 40353578
More about the evidence
Evidence is strong for FDA-approved semaglutide products in chronic weight management. Evidence should not automatically be transferred to every compounded concentration, salt, route or custom-dose strategy.
Sources
- Wegovy (semaglutide) prescribing information, DailyMed
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025
- He L et al. GLP-1 receptor agonist use and risk of gallbladder and biliary diseases: systematic review and meta-analysis. JAMA Intern Med. 2022
Common side effects
Nausea, vomiting, diarrhea, constipation, abdominal discomfort and reflux are among the most common effects.
What may help
Stomach-related side effects are usually most noticeable when starting treatment or after a dose increase, and often ease over time. General measures that may help:
- Eat smaller meals and stop when you first feel full.
- Eat slowly, and avoid lying down right after eating.
- Go easier on greasy, fried or very rich foods if they make symptoms worse.
- Drink fluids steadily through the day, especially if you have vomiting or diarrhea.
- For constipation, fluids and fiber-containing foods may help.
- Include protein at meals and keep up regular activity, including strength exercise if it is appropriate for you, to help protect muscle during weight loss.
Do not change your dose or stop treatment on your own. If symptoms persist or get in the way of eating and drinking, your clinician can review your plan.
Suggested add-ons: ondansetron for nausea and trazodone for sleep, chosen in the same GLP-1 intake. See the add-ons
Important safety information
Pregnancy and fertility. Not for use during pregnancy. The FDA label for semaglutide 2.4 mg (Wegovy) advises stopping at least 2 months before a planned pregnancy. Tell your clinician if you are pregnant, planning a pregnancy or breastfeeding.
Important considerations include personal/family history of medullary thyroid carcinoma or MEN2, pancreatitis, gallbladder disease, dehydration and kidney injury, severe gastrointestinal problems, pregnancy and medication interactions. Compounded semaglutide is not FDA-approved.
This is a compounded medication. Compounded medications are prepared by licensed pharmacies and are not FDA-approved.
Compounded semaglutide and tirzepatide are prepared by licensed pharmacies and are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Available by prescription only, following evaluation by a licensed clinician. Not appropriate for everyone and not available in all states. Individual results vary.
When to seek urgent care
Contact your clinician promptly if you have vomiting or diarrhea that does not settle, signs of dehydration (dizziness, very dark urine, passing little urine), or symptoms that stop you eating or drinking.
Seek urgent care for severe stomach pain that does not go away (with or without vomiting), pain in the upper right abdomen with fever or yellowing of the skin or eyes, a lump or swelling in the neck with trouble swallowing or persistent hoarseness, or signs of a serious allergic reaction such as swelling of the face, lips or throat or difficulty breathing.
Before any surgery or procedure that uses sedation, tell the care team you take a GLP-1 medication.
What you may have heard about GLP-1s
Nausea, vomiting, diarrhea and constipation
What people hear. GLP-1s make everyone sick.
What the evidence shows. Stomach-related side effects are the most common. In the approved-product trials, nausea affected 44% of people on semaglutide 2.4 mg (16% on placebo) and 25% to 29% on tirzepatide (8% on placebo). Most cases were mild to moderate, happened during dose increases and often eased with time.
What may help. Smaller meals, eating slowly and stopping when you first feel full. Going easier on greasy or very rich foods. Steady fluids, and fiber with fluids for constipation. Clinicians may slow the pace of dose increases.
When to contact a clinician. Vomiting or diarrhea that does not settle, signs of dehydration such as dizziness or very dark urine, or being unable to keep fluids down.
Muscle and lean-mass loss
What people hear. You lose muscle, not fat.
What the evidence shows. Most weight lost in the trials was fat. In body-composition substudies of STEP 1 and SURMOUNT-1, lean mass fell by about 10% while fat mass fell more (about 19% and 34%), so the share of lean mass in the body went up. Scans count water and organ tissue as lean mass too, not only muscle. Some lean-mass loss happens with most significant weight loss, and how much it affects strength and function is still being studied.
What may help. Protein at every meal, regular strength training if it is appropriate for you, and staying active. Your clinician can suggest what fits your health.
When to contact a clinician. Noticeable weakness, falls, or trouble with everyday activities.
Bone density and fractures
What people hear. GLP-1s weaken your bones.
What the evidence shows. Significant weight loss by any method can be accompanied by some loss of bone density, partly because bones carry less load and partly because nutrition and body composition change. In one randomized trial, adults taking the GLP-1 medicine liraglutide alone lost some hip and spine bone density, while those who combined it with regular exercise did not. Bone-density changes are not the same as fractures, and evidence on fracture risk with GLP-1 treatment is limited and mixed.
What may help. Weight-bearing and strength exercise if appropriate, and enough protein, calcium and vitamin D from food or as your clinician recommends.
When to contact a clinician. A history of osteoporosis or fractures, a fall, or new bone pain.
Gallbladder problems
What people hear. GLP-1s cause gallstones.
What the evidence shows. Rapid weight loss itself raises gallstone risk. A 2022 analysis of 76 randomized trials found GLP-1 medicines were linked to a higher relative risk of gallbladder and bile-duct problems (about 37% higher overall), with more risk at higher doses, longer use and weight-loss doses. These events were still uncommon.
What may help. Knowing the warning signs matters most. Tell your clinician if you have had gallstones before.
When to contact a clinician. Pain in the upper right or middle of the abdomen, especially after eating, fever, or yellowing of the skin or eyes. Severe pain needs urgent care.
Pancreatitis
What people hear. GLP-1s cause pancreatitis.
What the evidence shows. Acute pancreatitis is listed as a warning on the labels. Large randomized trials have generally not shown a clear increase, while some observational studies have: a 2023 insurance-claims study of people using GLP-1 medicines for weight loss reported a higher rate than with another weight-loss medicine, though events were rare and the estimate was uncertain. The risk appears uncommon.
What may help. Tell your clinician about any history of pancreatitis, gallstones, heavy alcohol use or very high triglycerides.
When to contact a clinician. Severe, persistent pain in the upper abdomen that may spread to your back, with or without vomiting, needs urgent care.
Delayed stomach emptying and severe stomach symptoms
What people hear. GLP-1s paralyze your stomach.
What the evidence shows. Slowing stomach emptying is part of how these medicines reduce appetite. Severe or persistent symptoms are uncommon but have been reported, and the same 2023 claims study reported higher rates of gastroparesis and bowel obstruction diagnoses, based on small numbers. The labels warn about severe stomach reactions, and the medicines are not recommended for people with severe gastroparesis.
What may help. Small meals and stopping when full. Tell the care team before any surgery or procedure that uses sedation, because food may stay in the stomach longer.
When to contact a clinician. Vomiting that will not stop, being unable to keep food or fluids down, severe bloating or abdominal pain, or no bowel movement with pain.
Hair shedding
What people hear. GLP-1s make your hair fall out.
What the evidence shows. Hair loss was reported slightly more often than with placebo in the approved-product trials: about 3% vs 1% with semaglutide 2.4 mg, and 4% to 5% vs 1% with tirzepatide. Shedding after rapid or large weight loss (telogen effluvium) is a recognized pattern with weight loss of any cause and is usually temporary.
What may help. Enough protein and a balanced diet, gentle hair care, and patience: this kind of shedding usually settles within months.
When to contact a clinician. Heavy or patchy hair loss, or shedding that lasts more than about six months.
Stopping treatment and weight regain
What people hear. The weight all comes back when you stop.
What the evidence shows. Often a good part of it does. One year after stopping semaglutide in the STEP 1 extension, participants had regained about two-thirds of the weight they had lost. In SURMOUNT-4, people switched from tirzepatide to placebo regained about 14% of body weight over the next year, while those who continued kept losing. Obesity behaves like a long-term condition.
What may help. Planning with your clinician for what comes next, and building eating and activity habits during treatment that you can keep.
When to contact a clinician. Before stopping or changing treatment, or if cost or side effects make continuing hard.
The thyroid warning
What people hear. GLP-1s cause thyroid cancer.
What the evidence shows. Semaglutide and tirzepatide carry a boxed warning because they caused thyroid C-cell tumors in rodents. It is not known whether they cause these tumors in people. They are not used in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2).
What may help. Share your personal and family history during intake so the clinician can check.
When to contact a clinician. A lump or swelling in the neck, trouble swallowing, persistent hoarseness or shortness of breath.
Questions people ask
Is this Ozempic or Wegovy?
No. The active molecule may be semaglutide, but a compounded formulation is not the branded FDA-approved product and should not be marketed as equivalent.
Is semaglutide a hormone?
It is a peptide medication designed to activate the receptor for the GLP-1 hormone.
Is tirzepatide stronger than semaglutide?
In a head-to-head trial of FDA-approved injectable products in adults with obesity without diabetes, tirzepatide produced greater average weight loss than semaglutide. That is an average study result, not a guarantee that an individual will respond better or tolerate one better.
What side effects are most common?
Gastrointestinal effects are the most common with GLP-1 and GIP/GLP-1 treatment: nausea, diarrhea, vomiting, constipation, abdominal discomfort and indigestion/reflux. They are often dose-related, which is why treatment is usually approached gradually.
Why do I feel nauseated?
These medicines slow how quickly the stomach empties and act on appetite signals. Nausea was the most common side effect in the approved-product trials: 44% with semaglutide 2.4 mg versus 16% with placebo, and 25% to 29% with tirzepatide versus 8% with placebo. It is usually worst during dose increases and often improves. Smaller meals and eating slowly may help. Vomiting that does not settle needs medical review.
Will I lose muscle?
In body-composition substudies of the STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) trials, most of the weight lost was fat, but lean mass also fell by about 10% from where participants started. Some lean-mass loss happens with most significant weight loss, whatever the method. Getting enough protein and doing regular strength exercise may help preserve muscle; ask your clinician what is appropriate for you.
Complete your care
Other treatments available through Avono, each reviewed separately by a licensed clinician. Same pricing: no membership fees, no clinician fees, free shipping.
Your secure online visit takes a few minutes.
Discuss Semaglutide Injection with a licensed clinician
Your clinician reviews your health history and decides whether this option, or another, is appropriate.
$79 per month
Your secure online visit takes a few minutes.
Semaglutide Injection $79 / month